
Calithera Biosciences CALA
Calithera Biosciences ROE | CALA
ROE Jährlich Calithera Biosciences
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| -194.44 | -1373.04 | -88.05 | -63.09 | -43.11 | -18.51 | -76.15 | -45.47 | -21.63 | 59.47 | 93.05 | - |
Jährliche Entwicklung
Kennzahlen zur Anzeige auswählen
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 93.05 | -1373.04 | -161.0 |
ROE Vierteljährlich Calithera Biosciences
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 378.27 | 363.26 | 383.17 | 387.25 | -53.91 | -72.46 | -71.67 | -73.58 | -51.92 | -67.18 | -65.45 | -68.55 | -71.75 | -71.89 | -68.94 | -53.7 | -40.28 | -32.19 | -22.16 | -23.27 | -17.71 | -29.48 | -41.52 | -56.12 | -66.99 | -59.15 | -54.6 | -45.86 | -40.06 | -35.63 | -9.34 | -5.76 | -1.45 | 21.3 | -5.47 | -4.13 | - | 15.94 | - | - | - | - | - | - | - | - | - | - |
Quartalsentwicklung
Kennzahlen zur Anzeige auswählen
Alle Zahlen in USD-Währung
Indikatorspanne aus vierteljährlicher Berichterstattung
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 387.25 | -73.58 | 4.51 |
ROE anderer Aktien in der Pharmaeinzelhändler
| Name | ROE | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
Reata Pharmaceuticals
RETA
|
474.77 | - | - | $ 6.29 B | ||
|
PainReform Ltd.
PRFX
|
-58.78 | $ 0.47 | -24.53 % | $ 305 K | ||
|
iTeos Therapeutics
ITOS
|
-22.77 | - | - | $ 411 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
-175.75 | $ 1.44 | -2.03 % | $ 2.37 M | ||
|
PolarityTE
PTE
|
-47.14 | - | -0.82 % | $ 1.78 M | ||
|
Kronos Bio
KRON
|
-98.29 | - | 1.49 % | $ 50.8 M | ||
|
Cullinan Management
CGEM
|
-53.8 | $ 8.9 | -1.93 % | $ 536 M | ||
|
CRISPR Therapeutics AG
CRSP
|
-30.26 | $ 39.15 | 0.57 % | $ 3.52 B | ||
|
Advaxis
ADXS
|
196.88 | - | -9.65 % | $ 45.9 M | ||
|
Stoke Therapeutics
STOK
|
-1.95 | $ 26.77 | -0.59 % | $ 1.59 B | ||
|
Trevena
TRVN
|
526.17 | - | -46.58 % | $ 31.8 M | ||
|
Molecular Templates
MTEM
|
-192.88 | - | -23.43 % | $ 495 K | ||
|
Oncorus
ONCR
|
-127.92 | - | -8.54 % | $ 3.19 M | ||
|
BioXcel Therapeutics
BTAI
|
73.22 | $ 0.07 | 9.81 % | $ 855 K | ||
|
Novan
NOVN
|
-679.93 | - | -24.84 % | $ 2.64 M | ||
|
CohBar
CWBR
|
-79.41 | - | -15.44 % | $ 2.2 M | ||
|
NeuBase Therapeutics
NBSE
|
-23.97 | - | -1.56 % | $ 12.3 M | ||
|
Epizyme
EPZM
|
1213.85 | - | - | $ 249 M | ||
|
Arena Pharmaceuticals
ARNA
|
-91.56 | - | -6.81 % | $ 3.04 B | ||
|
Scopus BioPharma
SCPS
|
176.86 | - | -48.37 % | $ 3.71 M | ||
|
Nabriva Therapeutics plc
NBRV
|
-1736.56 | - | - | $ 4.55 M | ||
|
Annovis Bio
ANVS
|
-171.23 | $ 0.71 | -3.81 % | $ 14.6 M | ||
|
scPharmaceuticals
SCPH
|
-639.25 | - | - | $ 218 M | ||
|
Entasis Therapeutics Holdings
ETTX
|
-151.03 | - | - | $ 105 M | ||
|
Athersys
ATHX
|
304.11 | - | 3.77 % | $ 22.4 M | ||
|
Global Blood Therapeutics
GBT
|
-154.32 | - | - | $ 4.62 B | ||
|
Inozyme Pharma
INZY
|
-176.43 | - | - | $ 207 M | ||
|
NanoString Technologies
NSTG
|
-348.24 | - | -37.43 % | $ 5.1 M | ||
|
Humanigen
HGEN
|
151.25 | - | -81.12 % | $ 4.28 M | ||
|
CNS Pharmaceuticals
CNSP
|
-350.48 | $ 3.56 | -9.07 % | $ 1.58 M | ||
|
Sorrento Therapeutics
SRNE
|
3078.97 | - | -29.58 % | $ 126 M | ||
|
Surface Oncology
SURF
|
-68.08 | - | - | $ 59.7 M | ||
|
Sierra Oncology
SRRA
|
-98.61 | - | -0.05 % | $ 1.34 B | ||
|
Vaccinex
VCNX
|
748.95 | - | -61.37 % | $ 654 K | ||
|
Nymox Pharmaceutical Corporation
NYMX
|
66.3 | - | -19.68 % | $ 18.4 M | ||
|
Jounce Therapeutics
JNCE
|
-27.81 | - | - | $ 98.4 M | ||
|
Cocrystal Pharma
COCP
|
-139.49 | $ 0.93 | -4.11 % | $ 10.5 M | ||
|
Fortress Biotech
FBIO
|
74.19 | $ 1.89 | 6.78 % | $ 52.7 M | ||
|
Acorda Therapeutics
ACOR
|
160.08 | - | -24.86 % | $ 820 K | ||
|
Longeveron
LGVN
|
-400.07 | $ 1.65 | -9.34 % | $ 29 B | ||
|
Ampio Pharmaceuticals
AMPE
|
-256.9 | - | -11.43 % | $ 502 K | ||
|
Immunic
IMUX
|
1456.2 | $ 7.0 | -5.28 % | $ 1.09 B | ||
|
Immunovant
IMVT
|
-59.3 | $ 31.74 | -2.4 % | $ 5.79 B | ||
|
Mersana Therapeutics
MRSN
|
727.65 | - | - | $ 3.56 B | ||
|
Akari Therapeutics, Plc
AKTX
|
-61.07 | $ 6.83 | 1.71 % | $ 460 B | ||
|
MediWound Ltd.
MDWD
|
-126.46 | $ 13.59 | 0.33 % | $ 370 M | ||
|
CymaBay Therapeutics
CBAY
|
-36.05 | - | - | $ 3.45 B | ||
|
Freeline Therapeutics Holdings plc
FRLN
|
-169.75 | - | - | $ 384 M | ||
|
Keros Therapeutics
KROS
|
28.7 | $ 11.04 | -3.07 % | $ 411 M |